February 23, 2021
1 min read
ADD TOPIC TO EMAIL ALERTS
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
ADDED TO EMAIL ALERTS
We were unable to process your request. Please try again later. If you continue to have this issue please contact email@example.com.
Back to Healio
The FDA granted fast track designation to GEN-1 for treatment of advanced ovarian cancer, according to the agent’s manufacturer.
GEN-1 (Celsion) is a DNA-mediated interleukin-12 immunotherapy.
Source: Adobe Stock.
“Fast track designation is an important step in developing GEN-1 for advanced ovarian cancer,” Michael H. Tardugno, Celsion’s chairman, president and CEO, said in a company-issued press release. “Presuming the encouraging data we are generating in early clinical studies continues, this designation supports an expedited path to market. … We are optimistic that GEN-1 represents a game-changer for women with advanced ovarian cancer who have limited treatment options.”
The phase 2 OVATION 2 study is evaluating the addition of GEN-1 to standard neoadjuvant chemotherapy for women with newly diagnosed stage III/stage IV ovarian cancer…